PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS)

$0.06805 -0.00127 (-1.8321%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 51

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS) News Sources

Provectus: Q3 Earnings Snapshot

13-11-2025

yahoo.com

Provectus: Q4 Earnings Snapshot

26-03-2026

yahoo.com

Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment

02-04-2026

yahoo.com

Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee

20-04-2026

yahoo.com

Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis

04-05-2026

yahoo.com

Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End

18-05-2026

yahoo.com

Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders

08-06-2026

yahoo.com

Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)

25-06-2026

yahoo.com

Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections

30-06-2026

yahoo.com

Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose

07-07-2026

yahoo.com

PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS) Sentiment Trend

0 25 50 75 100 4 5 57 58 64 40 65 86 67 67 13-11-2025 26-03-2026 02-04-2026 20-04-2026 04-05-2026 18-05-2026 08-06-2026 25-06-2026 30-06-2026 07-07-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS) FAQs

toggle

What is the current price of PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS)?

The current price of PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS) is $0.06805.


toggle

PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS) absolute price change since previous trading day?

The absolute price change of PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS) since the previous trading day is $-0.00127.


toggle

PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS) percentage price change since previous trading day?

The percentage price change of PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS) since the previous trading day is -1.8321%.


toggle

What is the most recent average sentiment score for PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS)?

The most recent average sentiment score for PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS) is 51 out of 100.


toggle

What is the most recent average sentiment for PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS)?

The most recent sentiment for PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS) is .


SEC-8K** Filing Available For PROVECTUS BIOPHARMACEUTICA-A (PVCT:OTCMKTS)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.